# Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

> **NCT07262476** · PHASE3 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 258 (estimated)

## Conditions studied

- Thyroid Eye Disease (TED)

## Interventions

- **DRUG:** MHB018A injection

## Key facts

- **NCT ID:** NCT07262476
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2029-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262476, "Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07262476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*